Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
Hims & Hers Health, Inc. earnings per share (EPS) for the twelve months ending Mar 03, 2025 was $0.6, a increase year-over-year.
As of Mar 03, 2025, Hims & Hers Health, Inc.'s P/E ratio is 73.5x. This is calculated by dividing the current share price of $40.7 by the Earnings per Share (EPS) for the trailing twelve months, which is $0.6. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
Hims & Hers Health, Inc. is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $22.2, compared to a market price of around $40.7. This suggests a potential overvaluation of 45.4%.